OBJECTIVE: The objective of the study was to determine the cost-effectiveness of annual screening tests for endometrial cancer. STUDY DESIGN: Markov state transition model of the natural history of endometrial cancer used as the design for the study. Incidence was modeled for the general population and high risk groups (obese, body mass index [BMI] of >or= 30 kg/m(2); tamoxifen users). Strategies evaluated were no screening, annual endometrial biopsy, annual endovaginal ultrasound, and annual serum screening. Serum screening was based on a recently described biomarker panel (sensitivity of 0.98, specificity of 0.98). RESULTS: In the general population model, no screening was least expensive, whereas annual serum screening age at 50-75 years had incremental cost-effectiveness ratio (ICER) of $60,363 per year of life saved (YLS) compared with no screening. In a high-risk population (obesity, BMI of >or= 30 kg/m(2)), annual serum screening at age 45-80 years had ICER of $41,226 per YLS compared with no screening. Annual endometrial biopsy and annual transvaginal ultrasound were dominated. CONCLUSION: Annual serum screening for endometrial cancer has the potential to be cost effective when applied to high-risk populations.
OBJECTIVE: The objective of the study was to determine the cost-effectiveness of annual screening tests for endometrial cancer. STUDY DESIGN: Markov state transition model of the natural history of endometrial cancer used as the design for the study. Incidence was modeled for the general population and high risk groups (obese, body mass index [BMI] of >or= 30 kg/m(2); tamoxifen users). Strategies evaluated were no screening, annual endometrial biopsy, annual endovaginal ultrasound, and annual serum screening. Serum screening was based on a recently described biomarker panel (sensitivity of 0.98, specificity of 0.98). RESULTS: In the general population model, no screening was least expensive, whereas annual serum screening age at 50-75 years had incremental cost-effectiveness ratio (ICER) of $60,363 per year of life saved (YLS) compared with no screening. In a high-risk population (obesity, BMI of >or= 30 kg/m(2)), annual serum screening at age 45-80 years had ICER of $41,226 per YLS compared with no screening. Annual endometrial biopsy and annual transvaginal ultrasound were dominated. CONCLUSION: Annual serum screening for endometrial cancer has the potential to be cost effective when applied to high-risk populations.
Authors: Maurizio De Luca; Luigi Angrisani; Jacques Himpens; Luca Busetto; Nicola Scopinaro; Rudolf Weiner; Alberto Sartori; Christine Stier; Muffazal Lakdawala; Aparna G Bhasker; Henry Buchwald; John Dixon; Sonja Chiappetta; Hans-Christian Kolberg; Gema Frühbeck; David B Sarwer; Michel Suter; Emanuele Soricelli; Mattias Blüher; Ramon Vilallonga; Arya Sharma; Scott Shikora Journal: Obes Surg Date: 2016-08 Impact factor: 4.129
Authors: Uri Ladabaum; Grace Wang; Jonathan Terdiman; Amie Blanco; Miriam Kuppermann; C Richard Boland; James Ford; Elena Elkin; Kathryn A Phillips Journal: Ann Intern Med Date: 2011-07-19 Impact factor: 25.391
Authors: Emily C Von Bargen; Cara L Grimes; Kavita Mishra; Rui Wang; Miriam J Haviland; Michele R Hacker; Joseph A Carnevale; Alyssa J Estes; Eman A Elkadry Journal: Int J Gynaecol Obstet Date: 2017-02-28 Impact factor: 3.561
Authors: Jamie N Bakkum-Gamez; Nicolas Wentzensen; Matthew J Maurer; Kieran M Hawthorne; Jesse S Voss; Trynda N Kroneman; Abimbola O Famuyide; Amy C Clayton; Kevin C Halling; Sarah E Kerr; William A Cliby; Sean C Dowdy; Benjamin R Kipp; Andrea Mariani; Ann L Oberg; Karl C Podratz; Viji Shridhar; Mark E Sherman Journal: Gynecol Oncol Date: 2015-02-10 Impact factor: 5.482
Authors: Michelle L Torres; Amy L Weaver; Sanjeev Kumar; Stefano Uccella; Abimbola O Famuyide; William A Cliby; Sean C Dowdy; Bobbie S Gostout; Andrea Mariani Journal: Obstet Gynecol Date: 2012-11 Impact factor: 7.661
Authors: Veronika Seebacher; Maximilian Schmid; Stephan Polterauer; Katrin Hefler-Frischmuth; Heinz Leipold; Nicole Concin; Alexander Reinthaller; Lukas Hefler Journal: BMC Cancer Date: 2009-12-22 Impact factor: 4.430
Authors: Maaike Alblas; Elisabeth F P Peterse; Mengmeng Du; Ann G Zauber; Ewout W Steyerberg; Nikki van Leeuwen; Iris Lansdorp-Vogelaar Journal: Cancer Med Date: 2021-09-12 Impact factor: 4.452